OOIR: Observatory of International Research

Papers

(The H4-Index of Cancer Letters is 62. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)

Article	Citations
Editorial Board	347
Ethnic Diversity and Metabolic Variations in Ovarian Cancer Cells: Implications for Personalized Medicine Strategies	304
Versatility of Exosomes for Cancer Therapy	289
Editorial Board	181
An emerging aspect of cancer neuroscience: A literature review on chemotherapy-induced peripheral neuropathy	169
Selpercatinib mitigates cancer cachexia independent of anti-tumor activity in the HT1080 tumor model	162
Nervous system in colorectal cancer	156
Bypassing the Tollway; a novel path to TLR4 independent stemness regulation	140
Editorial Board	139
Comparable survival outcomes in HLA-Matched and haploidentical hematopoietic stem cell transplantation for severe aplastic anemia patients aged 40–50: A CBMTR Registry-based propensity score matching	137
ASPH dysregulates cell death and induces chemoresistance in hepatocellular carcinoma	135
Targeted inhibition of acidic nucleoplasmic DNA-binding protein 1 enhances radiosensitivity of non-small cell lung cancer	121
Dual mTORC1/2 inhibitor AZD2014 diminishes myeloid-derived suppressor cells accumulation in ovarian cancer and delays tumor growth	121
Targeting p53 for immune modulation: Exploring its functions in tumor immunity and inflammation	114
The landscape of malignant transition: Unraveling cancer cell-of-origin and heterogeneous tissue microenvironment	111
Chaperone directed heterobifunctional molecules circumvent KRASG12C inhibitor resistance	104
CD147-specific chimeric antigen receptor T cells effectively inhibit T cell acute lymphoblastic leukemia	104
Corrigendum to “Selective degradation of FGFR1/2 overcomes antiestrogen resistance in ER+ breast cancer with FGFR1/2 alterations” [619 1 (2025) 217668 1–13]	102
PI3K inhibitor impairs tumor progression and enhances sensitivity to anlotinib in anlotinib-resistant osteosarcoma	101
A natural compound melatonin enhances the effects of Nimotuzumab via inhibiting EGFR in glioblastoma	101
Tuning cellular metabolism for cancer virotherapy	100
Integrated analysis of ascites and plasma extracellular vesicles identifies a miRNA-based diagnostic signature in ovarian cancer	99
The stromal microenvironment endows pancreatic neuroendocrine tumors with spatially specific invasive and metastatic phenotypes	96
Hormonal and neuronal interactions shaping the brain metastatic microenvironment	96
IBI379, a novel B cell maturation antigen/CD3 bispecific T-cell engager, displays high antitumor efficacy in preclinical models of multiple myeloma	96

TIM3 on natural killer cells regulates antibody-dependent cellular cytotoxicity in HER2-positive gastric cancer	95
Targeted inhibition of the expression of both MCM5 and MCM7 by miRNA-214 impedes DNA replication and tumorigenesis in hepatocellular carcinoma cells	93
Combination treatment with 17β-estradiol and anti-PD-L1 suppresses MC38 tumor growth by reducing PD-L1 expression and enhancing M1 macrophage population in MC38 colon tumor model	93
Understanding the significance of biological clock and its impact on cancer incidence	89
Sialic Acids: Sweet modulators fueling cancer cells and domesticating the tumor microenvironment	89
Tumor-targeted exosomes for delivery of anticancer drugs	88
Neoantigen discovery and applications in glioblastoma: An immunotherapy perspective	85
Intratumoral injection of mRNA encoding survivin in combination with STAT3 inhibitor stattic enhances antitumor effects	85
Coiled-coil domain-containing 154 promotes colorectal cancer proliferation and metastasis via interacting with minichromosome maintenance complex component 2	83
CSNK2A1 confers gemcitabine resistance to pancreatic ductal adenocarcinoma via inducing autophagy	83
FAP upregulates PD-L1 expression in cancer-associated fibroblasts to exacerbate T cells dysfunction and suppress anti-tumor immunity	80
The E3 ligase TRIM22 functions as a tumor suppressor in breast cancer by targeting CCS for proteasomal degradation to inhibit STAT3 signaling	79
Intracellular AGR2 transduces PGE2 stimuli to promote epithelial–mesenchymal transition and metastasis of colorectal cancer	78
M6A-modified lncRNA FAM83H-AS1 promotes colorectal cancer progression through PTBP1	77
METTL3 regulates M6A methylation-modified EBV-pri-miR-BART3-3p to promote NK/T cell lymphoma growth	76
LCAT deficiency promotes hepatocellular carcinoma progression and lenvatinib resistance by promoting triglyceride catabolism and fatty acid oxidation	75
Induction of EnR stress by Melatonin enhances the cytotoxic effect of Lapatinib in HER2-positive breast cancer	75
Metronomic chemotherapy regimens and targeted therapies in non-Hodgkin lymphoma: The best of two worlds	75
Sphingosine-1 phosphate receptor 1 (S1PR1) expression maintains stemness of acute myeloid leukemia stem cells	72
Regulation of gut microbiota on immune cell ferroptosis: A novel insight for immunotherapy against tumor	71
MDSCs in bone metastasis: Mechanisms and therapeutic potential	70
Valproate and lithium: Old drugs for new pharmacological approaches in brain tumors?	70
The role of Hippo/YAP1 in cancer-associated fibroblasts: Literature review and future perspectives	69
ERBB3 targeting: A promising approach to overcoming cancer therapeutic resistance	69
Hypoxia effects on glioblastoma progression through YAP/TAZ pathway regulation	69
Evaluation and preservation of fertility in patients with hematologic malignancies	68
Accelerating the clinical translation of CD70-targeted chimeric antigen receptor-based cell therapies in oncology: A comprehensive clinical investigation panorama analysis based on the Trialtrove data	67
The interplay between autophagy and apoptosis: its implication in lung cancer and therapeutics	67
Unscheduled polyploidy synergizes with oncogenic mutations to enhance genome instability and tumorigenesis.	67
CD155 in tumor progression and targeted therapy	67
KAT7 enhances the proliferation and metastasis of head and neck squamous carcinoma by promoting the acetylation level of LDHA	64
PROTACs: Novel tools for improving immunotherapy in cancer	63
Clinical development of immuno-oncology therapeutics	63
Osteopontin promotes tumor microenvironment remodeling and therapy resistance	63
Fatty acids in cancer chemoresistance	62
Increasing membrane polyunsaturated fatty acids sensitizes non-small cell lung cancer to anti-PD-1/PD-L1 immunotherapy	62
Calcium channel TRPV6 promotes breast cancer metastasis by NFATC2IP	62
Targeting LINC01607 sensitizes hepatocellular carcinoma to Lenvatinib via suppressing mitophagy	62